SPY072

DRUG2 trials

Sponsors

Spyre Therapeutics Inc., Spyre Therapeutics, Inc.

Conditions

Hidradenitis Suppurativa (HS)Moderately to Severely Active Rheumatologic Disease

Phase 2

Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease

RecruitingCTIS2025-521791-63-00

Spyre Therapeutics Inc.Moderately to Severely Active Rheumatologic Disease

Start: 2025-12-18Target: 236Updated: 2025-12-08

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Not yet recruitingNCT07766005

Spyre Therapeutics, Inc.Hidradenitis Suppurativa (HS)

Start: 2026-09-01End: 2028-06-01Target: 150Updated: 2026-08-14